<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1606">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157712</url>
  </required_header>
  <id_info>
    <org_study_id>ALZ-801-103</org_study_id>
    <nct_id>NCT04157712</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of ALZ-801</brief_title>
  <official_title>A Phase I, Single Centre, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics in Plasma and Urine of Multiple Ascending Doses of ALZ-801 in Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alzheon Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alzheon Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, single-center, double-blind, randomized, placebo-controlled, parallel-group study of&#xD;
      the safety, tolerability, and pharmacokinetics (PK) in plasma and urine, of multiple&#xD;
      ascending doses of ALZ-801 (capsule, Part 1; prototype tablet Part 2) and the primary&#xD;
      metabolite in healthy male or female subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was conducted in two parts:&#xD;
&#xD;
      Part 1 Primary objective: To evaluate the safety, tolerability, and pharmacokinetics, of&#xD;
      multiple doses of ALZ-801 capsule formulation in healthy elderly subjects.&#xD;
&#xD;
      Methodology: Phase I, single center, in-patient and out-patient, double-blind, randomized,&#xD;
      placebo-controlled, parallel-group study of the safety, tolerability and pharmacokinetics&#xD;
      (PK) in plasma and urine of multiple ascending doses of ALZ-801 in healthy male or female&#xD;
      subjects aged 50 to 75 years, inclusive. A total of 36 subjects were enrolled into 3&#xD;
      successive cohorts (A, B, C with 12 subjects per cohort) and randomized in a 3:1 ratio to&#xD;
      receive treatment with ALZ-801 capsules (9 subjects) or placebo capsules (3 subjects) for 2&#xD;
      weeks. Progression to the next cohort was permitted after review of safety and available PK&#xD;
      data suggested that it was safe to do so. Subjects were confined to the clinical unit for the&#xD;
      first day of dosing (Day 1 and for Days 7 through 14). Subjects took investigational drug at&#xD;
      home for Days 2 through 6).&#xD;
&#xD;
      Cohorts A was dosed in the fasted state and evaluated 171 mg ALZ-801 or placebo QD for 1 day,&#xD;
      followed by 171 mg ALZ-801 or placebo BID for 6 days and 256.5 mg or placebo QD for 7 days.&#xD;
&#xD;
      Cohort B was dosed in the fasted state and evaluated 256.5 mg ALZ-801 or placebo QD for 1&#xD;
      day, followed by 256.5 mg ALZ-801 or placebo BID for 6 days and 340 mg or placebo QD for 7&#xD;
      days.&#xD;
&#xD;
      Cohort C was dosed in the fed state and evaluated 256.5 mg ALZ-801 or placebo QD for 1 day,&#xD;
      followed by 256.5 mg ALZ-801 or placebo BID for 6 days, then 340 mg or placebo BID for 6 days&#xD;
      and 340 mg or placebo QD for 1 day.&#xD;
&#xD;
      Part 2 Primary objective: To evaluate the safety, tolerability, and pharmacokinetics, of&#xD;
      multiple doses of prototype ALZ-801 tablet formulation in healthy elderly subjects.&#xD;
&#xD;
      Methodology: Phase I, single center, in-patient and out-patient, double-blind, randomized,&#xD;
      placebo-controlled, parallel-group study of the safety, tolerability and pharmacokinetics&#xD;
      (PK) in plasma and urine of multiple ascending doses of ALZ-801 in healthy male or female&#xD;
      subjects aged 60 to 75 years, inclusive. A total of 12 subjects were enrolled into one cohort&#xD;
      (D) and randomized in a 3:1 ratio to receive treatment with ALZ-801 tablets (9 subjects) or&#xD;
      placebo capsules (3 subjects) for 1 week.&#xD;
&#xD;
      Cohort D was dosed in the fed state and evaluated 265 mg ALZ-801 or placebo QD for 1 day,&#xD;
      followed by 265 mg ALZ-801 prototype tablet or placebo BID for 5 days, 265 mg or placebo QD&#xD;
      for 1 day.&#xD;
&#xD;
      For all subjects in the study blood and urine samples for the determination of concentrations&#xD;
      of ALZ-801, and its metabolites, were collected for up to 24 h after the first dose of&#xD;
      medication on Day1; and for up to 48 hours after the last dose of medication on Day 7 (Cohort&#xD;
      D) or Day 14 (Cohorts A, B and C). All subjects had blood samples and safety assessment at 72&#xD;
      and 96 hours after the final dose of medication. All subjects returned for a post treatment&#xD;
      follow-up 7-10 days after the last dose of study medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2015</start_date>
  <completion_date type="Actual">July 4, 2016</completion_date>
  <primary_completion_date type="Actual">July 4, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>double blind, placebo controlled, matching placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind, placebo controlled, matching placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Duration of dosing: 14 days for Part 1; 7 days for Part 2</time_frame>
    <description>Incidence and nature of adverse events (AEs) and serious adverse events (SAEs). Assessments reported as AEs or SAEs include physical examination, clinical laboratory tests, and 12-lead electrocardiogram (ECG) findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for ALZ-801 and tramiprosate</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
    <description>Maximum concentration after dosing [Cmax] measured as ng/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for ALZ-801 and tramiprosate</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
    <description>Time to reach Cmax [Tmax] measured in hours (h) after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for ALZ-801 and tramiprosate</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
    <description>AUC from time zero to time t (AUCt)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 for ALZ-801 and tramiprosate</measure>
    <time_frame>Days 1, 7, 14</time_frame>
    <description>Elimination half-life (t1/2) measured in hours after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance of ALZ-801 and tramiprosate</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
    <description>Clearance (CLr) measured in mL/min</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Cohort A Capsule - Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALZ-801 171 mg or matching placebo once daily Day 1, ALZ-801 171 mg or matching placebo twice daily Days 2-7, ALZ-801 256.5 mg or matching placebo once daily Days 8-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B Capsule - Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 or matching placebo mg twice daily Days 2-7, ALZ-801 340 mg or matching placebo once daily Days 8-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C Capsule - Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 mg or matching placebo twice daily Days 2-7, ALZ-801 340 mg or matching placebo twice daily Days 8-13, ALZ-801 340 mg or matching placebo once daily Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D Tablet - Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALZ-801 265 mg or matching placebo once daily Day 1, ALZ-801 265 mg or matching placebo twice daily Days 2-6, ALZ-801 265 mg or matching placebo once daily Day 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALZ-801 or matching placebo</intervention_name>
    <arm_group_label>Cohort A Capsule - Fasted</arm_group_label>
    <arm_group_label>Cohort B Capsule - Fasted</arm_group_label>
    <arm_group_label>Cohort C Capsule - Fed</arm_group_label>
    <arm_group_label>Cohort D Tablet - Fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males, and females&#xD;
&#xD;
          -  Age: 50-75 years, Part 1; 60-75 years Part 2&#xD;
&#xD;
          -  Females must be of non-childbearing potential&#xD;
&#xD;
          -  Body Mass Index 18-35 kg/m squared;&#xD;
&#xD;
          -  Vital signs normal for age: BP 90-160/40-90 mmHg; HR 50 to 90 bpm)&#xD;
&#xD;
          -  No clinically significant electrocardiogram readings&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body weight &lt; 50 kg&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  Subjects known to have a creatinine clearance of &lt;60 mL/min&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
          -  History of clinically significant cardiovascular, pulmonary, chronic respiratory,&#xD;
             renal, hepatic, GI, immunologic, endocrine, neurologic, psychiatric or thromboembolic&#xD;
             disease&#xD;
&#xD;
          -  History of metabolic disturbances;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pui Leung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Hey JA, Yu JY, Versavel M, Abushakra S, Kocis P, Power A, Kaplan PL, Amedio J, Tolar M. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57(3):315-333. doi: 10.1007/s40262-017-0608-3.</citation>
    <PMID>29063518</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

